Navigation Links
Vioxx Settlement Announced
Date:11/9/2007

TAMPA, Fla., Nov. 9 /PRNewswire/ -- After several years of litigation, Merck has agreed to pay $4.85 billion in a settlement over Vioxx. The medication was pulled off the market in 2004 after a clinical trial proved it increased the risks of heart attacks and strokes. It is one of the largest pharmaceutical settlements in history.

James Hoyer Newcomer and Smiljanich is pleased this long process is coming to a resolution. The firm has more than a dozen clients who've suffered the ill-effects of taking Vioxx. "This settlement was a long time coming, but one that will finally give our clients some relief from the harm they suffered," said Attorney John Newcomer.

Nearly 30-thousand lawsuits have been filed nationwide against Merck because of Vioxx. Plaintiffs will receive different settlement payments depending on the severity of their injuries and the length of time they took Vioxx. Plaintiff Alvin Jupiter, of Tampa, suffered a heart attack in 2001 after taking Vioxx. He said, "I'm glad to see something coming to fruition on this. So many people were hurt."

James Hoyer Newcomer & Smiljanich will review details of the settlement over the coming weeks and work to ensure our clients are compensated fairly.


'/>"/>
SOURCE James Hoyer Newcomer & Smiljanich
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. New study may explain Vioxx side-effects
2. Study Points to Cause of Vioxx Heart Risk
3. Vioxx Ban Tied to Rise in Serious GI Trouble
4. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
5. Vioxx Settlement Puts Painkillers Back in the Spotlight
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
8. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
9. $52.5 Million Settlement Against Sepracor Inc. Approved
10. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
11. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... broad access to life-saving drugs and rewarding the innovators who develop those drugs often ... , That was the message from Dana Goldman, PhD, Leonard D. Schaeffer Chair and ... who served as the keynote speaker for Western University of Health Sciences’ Ray Symposium ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 ... proportion of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
Breaking Medicine Technology: